Gladys Urbanowitz

5.8k total citations · 4 hit papers
12 papers, 4.2k citations indexed

About

Gladys Urbanowitz is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Gladys Urbanowitz has authored 12 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 4 papers in Molecular Biology and 4 papers in Oncology. Recurrent topics in Gladys Urbanowitz's work include Renal cell carcinoma treatment (5 papers), Bone health and treatments (4 papers) and Cancer Diagnosis and Treatment (3 papers). Gladys Urbanowitz is often cited by papers focused on Renal cell carcinoma treatment (5 papers), Bone health and treatments (4 papers) and Cancer Diagnosis and Treatment (3 papers). Gladys Urbanowitz collaborates with scholars based in United States, South Korea and France. Gladys Urbanowitz's co-authors include Thomas E. Hutson, Bernard Escudier, Norbert Hollaender, Alain Ravaud, Robert J. Motzer, Andrea Kay, Sergio Bracarda, Camillo Porta, Stéphane Oudard and Robert A. Figlin and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer.

In The Last Decade

Gladys Urbanowitz

12 papers receiving 4.1k citations

Hit Papers

Efficacy of everolimus in advanced renal cell carcinoma: ... 2003 2026 2010 2018 2008 2017 2003 2004 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
    2008 2.3k citations Robert J. Motzer, Bernard Escudier et al. The Lancet profile →
  2. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer
    2017 607 citations Vivek Subbiah, Robert J. Kreitman et al. Journal of Clinical Oncology profile →
  3. Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial—The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group
    2003 557 citations Lee S. Rosen, David Gordon et al. Journal of Clinical Oncology profile →
  4. Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors
    2004 507 citations Lee S. Rosen, David Gordon et al. Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gladys Urbanowitz United States 8 2.2k 2.0k 1.9k 996 575 12 4.2k
Pablo Maroto Spain 27 1.8k 0.8× 1.5k 0.8× 1.3k 0.7× 763 0.8× 1.7k 2.9× 164 3.9k
Lina Asmar United States 42 2.7k 1.2× 3.9k 1.9× 926 0.5× 2.1k 2.2× 605 1.1× 169 6.4k
Kanishka Sircar United States 34 2.5k 1.1× 892 0.4× 1.6k 0.8× 1.0k 1.0× 1.3k 2.2× 91 4.2k
M. Tubiana-Hulin France 30 875 0.4× 3.3k 1.6× 921 0.5× 1.7k 1.7× 381 0.7× 60 4.6k
William R. Berry United States 11 3.9k 1.8× 1.8k 0.9× 985 0.5× 1.1k 1.1× 288 0.5× 22 4.9k
W. Kwasny Austria 27 727 0.3× 2.4k 1.2× 584 0.3× 1.9k 1.9× 290 0.5× 56 3.5k
Matthew M. Cooney United States 24 3.6k 1.6× 1.8k 0.9× 1.0k 0.5× 1.1k 1.1× 367 0.6× 86 5.2k
Thierry Gil Belgium 22 2.1k 1.0× 1.1k 0.6× 668 0.3× 453 0.5× 841 1.5× 94 3.5k
Jean-Pascal Machiels Belgium 18 2.4k 1.1× 2.0k 1.0× 960 0.5× 848 0.9× 457 0.8× 36 4.5k
Gilles Romieu France 37 2.1k 1.0× 4.8k 2.4× 1.2k 0.6× 1.9k 1.9× 163 0.3× 136 6.2k

Countries citing papers authored by Gladys Urbanowitz

Since Specialization
Citations

This map shows the geographic impact of Gladys Urbanowitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gladys Urbanowitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gladys Urbanowitz more than expected).

Fields of papers citing papers by Gladys Urbanowitz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gladys Urbanowitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gladys Urbanowitz. The network helps show where Gladys Urbanowitz may publish in the future.

Co-authorship network of co-authors of Gladys Urbanowitz

This figure shows the co-authorship network connecting the top 25 collaborators of Gladys Urbanowitz. A scholar is included among the top collaborators of Gladys Urbanowitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gladys Urbanowitz. Gladys Urbanowitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Subbiah, Vivek, Robert J. Kreitman, Zev A. Wainberg, et al.. (2017). Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer. Journal of Clinical Oncology. 36(1). 7–13. 607 indexed citations breakdown →
2.
Subbiah, Vivek, Robert J. Kreitman, Zev A. Wainberg, et al.. (2017). Efficacy of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated anaplastic thyroid cancer (ATC).. Journal of Clinical Oncology. 35(15_suppl). 6023–6023. 13 indexed citations
3.
Motzer, Robert J., Camillo Porta, Georg A. Bjarnason, et al.. (2012). Phase III trial of dovitinib (TKI258) versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogenic (VEGF-targeted and mTOR inhibitor) therapies.. Journal of Clinical Oncology. 30(15_suppl). TPS4683–TPS4683. 5 indexed citations
4.
Milowsky, Mathew I., et al.. (2011). A multicenter, open-label phase II trial of dovitinib (TKI258) in advanced urothelial carcinoma patients with either mutated or wild-type FGFR3.. Journal of Clinical Oncology. 29(15_suppl). TPS186–TPS186. 7 indexed citations
5.
Beaumont, Jennifer L., David Cella, Thomas E. Hutson, et al.. (2009). Patient-reported outcomes in a randomized trial of everolimus with metastatic renal cell carcinoma patients. Journal of Clinical Oncology. 27(15_suppl). e17516–e17516. 2 indexed citations
6.
Kay, Andrea, Robert J. Motzer, Robert A. Figlin, et al.. (2009). 257 UPDATED DATA FROM A PHASE 3 TRIAL OF EVEROLIMUS (RAD001) VERSUS PLACEBO IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA. European Urology Supplements. 8(4). 185–185. 16 indexed citations
7.
Motzer, Robert J., Bernard Escudier, Stéphane Oudard, et al.. (2008). Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. The Lancet. 372(9637). 449–456. 2339 indexed citations breakdown →
8.
Motzer, Robert J., Bernard Escudier, Stéphane Oudard, et al.. (2008). RAD001 vs placebo in patients with metastatic renal cell carcinoma (RCC)after progression on VEGFr-TKI therapy: Results from a randomized, double-blind, multicenter Phase-III study. Journal of Clinical Oncology. 26(15_suppl). LBA5026–LBA5026. 42 indexed citations
9.
Rosen, Lee S., David Gordon, N. Simon Tchekmedyian, et al.. (2004). Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors. Cancer. 100(12). 2613–2621. 507 indexed citations breakdown →
10.
Lipton, Allan, et al.. (2004). Skeletal Complications in Patients with Bone Metastases from Renal Cell Carcinoma and Therapeutic Benefits of Zoledronic Acid. Clinical Cancer Research. 10(18). 6397S–6403S. 70 indexed citations
11.
Rosen, Lee S., David Gordon, Simon Tchekmedyian, et al.. (2003). Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial—The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. Journal of Clinical Oncology. 21(16). 3150–3157. 557 indexed citations breakdown →
12.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pablo Maroto Breakdown of academic impact, for papers by Lina Asmar Breakdown of academic impact, for papers by Kanishka Sircar Breakdown of academic impact, for papers by M. Tubiana-Hulin Breakdown of academic impact, for papers by William R. Berry Breakdown of academic impact, for papers by W. Kwasny Breakdown of academic impact, for papers by Matthew M. Cooney Breakdown of academic impact, for papers by Thierry Gil Breakdown of academic impact, for papers by Jean-Pascal Machiels Breakdown of academic impact, for papers by Gilles Romieu
Rankless by CCL
2026